Key facts
- Everygene’s last known valuation is $19.4M (Dec 2025).
- It has raised $7.5M across 1 recorded rounds; the latest was Early Stage VC ($7.4M) in Nov 2025.
- Notable investors include The Artemis Fund.
- Everygene has filed 1 Form D with the SEC, most recently Dec 2025 ($7.4M sold to 16 investors).
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Everygene
Funding rounds
1 roundsAbout Everygene
Operator of a genetic testing company intended to provide free testing for patients. The company's platform offers free, clinically reviewed genetic testing for individuals diagnosed with cardiomyopathy, helping identify genetic variants that inform personalized treatment plans, enabling customers to understand their condition, reduce cardiac risks, and access tailored care and clinical trial opportunities.
- Sector
- Information Technology
- HQ
- Westport, CT, United States
- Founded
- 2023
- Employees
- 5
- Website
- everygene.com/
- Ownership
- Privately Held (backing)
Everygene doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Everygene shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Everygene in its N-PORT filings yet. We sweep new filings monthly.